T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan Inc
AGN
|
+$1.3B |
| 2 |
American Airlines Group
AAL
|
+$853M |
| 3 |
Intuitive Surgical
ISRG
|
+$816M |
| 4 |
Morgan Stanley
MS
|
+$681M |
| 5 |
Wynn Resorts
WYNN
|
+$622M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Procter & Gamble
PG
|
+$1.4B |
| 2 |
eBay
EBAY
|
+$763M |
| 3 |
DISCK
Discovery, Inc. Series C Common Stock
DISCK
|
+$760M |
| 4 |
Broadcom
AVGO
|
+$757M |
| 5 |
US Bancorp
USB
|
+$686M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.95% |
| 2 | Consumer Discretionary | 13.63% |
| 3 | Financials | 12.8% |
| 4 | Industrials | 12.27% |
| 5 | Technology | 9.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2051
Rithm Capital
RITM
$5.79B
| $381K | ﹤0.01% |
+30,200
| New | +$383K |
|
2052
Rush Enterprises Class A
RUSHA
$9.54B
| $381K | ﹤0.01% |
24,750
| – | – |
|
|
MCP
2053
DELISTED
MOLYCORP INC COM STK
MCP
| $379K | ﹤0.01% |
147,300
+61,700
| +72% | +$223K |
|
|
ELGX
2054
DELISTED
Endologix Inc
ELGX
| $376K | ﹤0.01% |
2,470
| – | – |
|
2055
Lattice Semiconductor
LSCC
$18.5B
| $375K | ﹤0.01% |
45,500
+11,200
| +33% | +$90.6K |
|
2056
Trex
TREX
$5.07B
| $375K | ﹤0.01% |
52,000
| – | – |
|
2057
Center Bancorp
CNOB
$1.8B
| $373K | ﹤0.01% |
19,383
| – | – |
|
|
BMTC
2058
DELISTED
Bryn Mawr Bank Corp
BMTC
| $373K | ﹤0.01% |
12,800
+800
| +7% | +$22.8K |
|
|
REIS
2059
DELISTED
Reis, Inc.
REIS
| $373K | ﹤0.01% |
17,700
| – | – |
|
2060
SunCoke Energy
SXC
$797M
| $372K | ﹤0.01% |
17,300
+7,600
| +78% | +$160K |
|
|
BCPC
2061
Balchem Corp
BCPC
$5.62B
| $372K | ﹤0.01% |
6,950
+1,500
| +28% | +$86.1K |
|
|
OUTR
2062
DELISTED
OUTERWALL INC
OUTR
| $371K | ﹤0.01% |
6,250
| – | – |
|
|
CSH
2063
DELISTED
CASH AMERICA INTERNATIONAL INC
CSH
| $371K | ﹤0.01% |
18,425
| – | – |
|
2064
BOK Financial
BOKF
$8.86B
| $370K | ﹤0.01% |
5,552
+1,300
| +31% | +$85K |
|
2065
Renasant Corp
RNST
$3.99B
| $370K | ﹤0.01% |
12,727
+1,300
| +11% | +$36.5K |
|
2066
Wabash National
WNC
$512M
| $369K | ﹤0.01% |
25,900
| – | – |
|
2067
Brink's
BCO
$4.68B
| $368K | ﹤0.01% |
13,049
| – | – |
|
|
ARNA
2068
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $367K | ﹤0.01% |
6,260
+700
| +13% | +$44.1K |
|
|
SFR
2069
DELISTED
Starwood Waypoint Homes
SFR
| $367K | ﹤0.01% |
14,000
-104,192
| -88% | -$2.84M |
|
2070
HEICO Corp
HEI
$52.1B
| $366K | ﹤0.01% |
17,205
-22,461
| -57% | -$505K |
|
|
SYKE
2071
DELISTED
SYKES Enterprises Inc
SYKE
| $366K | ﹤0.01% |
16,840
| – | – |
|
2072
WisdomTree
WT
$3.44B
| $365K | ﹤0.01% |
29,500
| – | – |
|
|
OMG
2073
DELISTED
OM GROUP INC.
OMG
| $365K | ﹤0.01% |
11,250
| – | – |
|
|
CTWS
2074
DELISTED
Connecticut Water Service Inc
CTWS
| $364K | ﹤0.01% |
10,750
+900
| +9% | +$29.4K |
|
2075
CDW
CDW
$17.6B
| $363K | ﹤0.01% |
11,400
| – | – |
|
Similar funds
T. Rowe Price Associates's Q2 2014 Portfolio in Review
As of Q2 2014, T. Rowe Price Associates held 2,596 positions worth $463B, up 3.9% from $445B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
T. Rowe Price Associates's Q2 2014 filing shows 97 new, 1,091 increased, 793 reduced and 67 closed positions. Its largest new stake was Teva Pharmaceuticals: 4,638,481 shares worth $243M. The largest sale was Procter & Gamble, an estimated $1.4B.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q2 2014 buy was Teva Pharmaceuticals: 4,638,481 shares worth $243M.
- T. Rowe Price Associates added most to Allergan Inc in Q2 2014, an estimated $1.3B increase.
- T. Rowe Price Associates's biggest Q2 2014 reduction was Procter & Gamble, cutting an estimated $1.4B.
- T. Rowe Price Associates fully exited Santander in Q2 2014, selling an estimated $134M.
- T. Rowe Price Associates's ten largest holdings make up 12% of its $463B portfolio in Q2 2014.
- T. Rowe Price Associates opened 97 new positions and closed 67 in Q2 2014.
- T. Rowe Price Associates's portfolio value rose 3.9% quarter-over-quarter to $463B.
Based on T. Rowe Price Associates's 13F filing for Q2 2014, filed 14 Aug 2014.